Sorafenib and Topotecan in Refractory/Recurrent Pediatric Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions
Solid Tumor
Interventions
DRUG

Topotecan

Topotecan will be given by mouth as outlined in treatment arm.

DRUG

Sorafenib

Sorafenib will be given by mouth as outlined in treatment arm.

Trial Locations (9)

10467

Montefiore Medical Center, Children's Hospital at Montefiore, The Bronx

19803

Nemours/Alfred I. duPont Hospital for Children, Delaware, Wilmington

32207

Nemours Children's Clinic, Jacksonville, Jacksonville

32610

University of Florida, Gainesville, Gainesville

33136

University of Miami, Sylvester Comprehensive Cancer Center, Miami

33701

All Children's Hospital, St. Petersburg, St. Petersburg

84113

Primary Children's Medical Center/Utah, Salt Lake City

90027

Childrens Hospital Los Angeles, Los Angeles

06106

Connecticut Childrens Medical Center, Hartford

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pediatric Cancer Foundation

OTHER

collaborator

Bayer

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER

NCT01683149 - Sorafenib and Topotecan in Refractory/Recurrent Pediatric Malignancies | Biotech Hunter | Biotech Hunter